Promising results for Biocept's OncoCEE-BR
February 23, 2015 at 12:09 PM EST
Columbia University published
promising results from a study of Biocept Inc.'s (Nasdaq: BIOC) blood-based
diagnostic OncoCEE-BR in determining hormonal status of metastatic
breast cancer patients sending the stock price soaring $1.30 to $2.75.
